

Streamline
Health®

Fourth Quarter and Fiscal 2021 Earnings Presentation
Nasdaq: STRM



Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.

TRADEMARKS


Product or company names referenced herein may be trademarks or registered trademarks of their respective owners

Fourth Quarter 2021 & Recent Highlights

SaaS Revenue



155% Growth of SaaS revenue in 4Q21 vs 4Q20. Driven by the acquisition of Avelead








Successful acquisition of Avelead expands revenue and product portfolio

\$13.9M

Fiscal 2021 New Bookings as of January 31, 2022

eValuator Solutions Update

-  Appointed Ben Stilwill to President & CEO, eValuator and Amy Sebero as Chief Growth Officer, eValuator
-  Signed third North Carolina Hospital System
-  Signed a seven-hospital, Epic-EHR based health system in Pennsylvania
-  Sustained pipeline growth: **17** new prospects added to eValuator pipeline in 4Q from resellers
-  Inside sales team added **\$11.3M** of TCV to pipeline during 4Q

Avelead Solutions Update

- **EHR-agnostic** suite of revenue cycle solutions that help healthcare providers capture **100%** of the revenue they've earned
- Flagship **RevID** solution compares posted charges to clinical information and is an ideal complement to eValuator
- Prioritizing improvements to innovation and service components – expanded leadership team with CTO and SVP Services
- Focused on leveraging opportunities through primary channel partner, Cerner for near term growth

Financial Results

Income Statement

	Three Months Ended January 31, 2022	Three Months Ended January 31, 2021	Twelve Months Ended January 31, 2022	Twelve Months Ended January 31, 2021
Revenue	\$6.0M	\$3.0M	\$17.4M	\$11.3M
Operating Expenses	\$8.2M	\$4.3M	\$28.1M	\$17.3M
Income (Loss) From Continuing Operations	(\$0.0M)	(\$1.6M)	(\$6.9M)	(\$4.8M)
Net Income/(Loss)	(\$0.0M)	(\$1.2M)	(\$6.4M)	\$0.3M
Adj. EBITDA*	(\$0.3M)	(\$0.1M)	(\$2.0M)	(\$1.9M)

*Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see our press release for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.


Financial Results

Balance Sheet

	As of January 31, 2022	As of January 31, 2021
Cash & Cash Equivalents	\$9.9M	\$2.4M
Total Current Assets	\$15.1M	\$7.3M
Total Current Liabilities	\$13.5M	\$7.4M
Total Bank Debt Outstanding	\$10.0M	\$0.0M

Looking Forward

- 2022 bookings target \$3-\$5M of SaaS TCV per quarter
- Project expansion of SaaS revenue throughout the year
- Anticipate reaching cash generation during 3Q 2023



Streamline
Health®

Fourth Quarter and Fiscal 2021 Earnings Presentation
Nasdaq: STRM

